Pancrelipase - Janssen Pharmaceuticals/VIVUS

Drug Profile

Pancrelipase - Janssen Pharmaceuticals/VIVUS

Alternative Names: Pancreaze

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ortho-McNeil-Janssen Pharmaceuticals
  • Developer VIVUS
  • Class Pancreatic enzymes
  • Mechanism of Action Pancrelipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 01 May 2018 Pancrelipase licensed to Vivus in USA and Canada
  • 04 Sep 2013 Janssen Pharmaceuticals, Aptalis Pharma and AbbVie initiate a porcine-virus safety trial in Cystic Fibrosis (NCT01858519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top